EVR compared with HALO: revenue, margins and what each company keeps, and the suppliers and customers both name

EVREvercore Inc.

Mkt capRevenueRevenue

HALOHalozyme Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

EVREvercore Inc.

HALOHalozyme Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

EVR2 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Oct 28 '26±8.1%▲+12.51%×1.54

Q2 FY26—▼−10.51%—

HALO1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±6.0%▲+20.24%×3.37

= impliedEVR realized, solidHALO realized, hatchedOne scale, both sides: full bar = 21%× = |realized| ÷ impliedSource: market data

EVREvercore Inc.

290.34· pre 290.32· delayed

Mkt cap$11.2BRevenue$2.9BQ2 FY26Revenue$11.5BFY25

HALOHalozyme Therapeutics, Inc.

130.89· pre 130.16· delayed

Pre-marketOct 30 '26delayed

Mkt cap$14.9BRevenue$481MQ2 FY26Revenue$1.4BFY25

Compare

Pre-marketOct 30 '26delayed

EVREvercore Inc.

HALOHalozyme Therapeutics, Inc.

290.34pre 290.32delayed

Price

130.89pre 130.16delayed

$11.2B

Mkt cap

$14.9B

Q2 FY26$2.9B

Revenue

$481MQ2 FY26

FY25$11.5B

Revenue

$1.4BFY25

EVR290.34vsHALO130.89Pre-marketOct 30 '26delayed